
Cahill Represents Underwriters in IPO by NewLink Genetics

Date: 11/16/11

Cahill represented Stifel Nicolaus Weisel and Canaccord Genuity as joint book-running managers in connection with a \$43,400,000 Initial Public Offering of 6,200,000 shares of common stock by biopharmaceutical company NewLink Genetics Corporation (Nasdaq: NLNK). The proceeds will be used for development of NewLink's pancreatic cancer and other immunotherapy product candidates and for general corporate purposes. NewLink's lead product candidate is currently in Phase 3 clinical testing.

Attorneys

- Geoffrey E. Liebmann
- Michael B. Weiss